Stya M, Wahl R L, Natale R B, Beierwaltes W H
NCI Monogr. 1987(3):19-23.
Small cell carcinoma of the lung is a highly lethal disease, killing nearly all patients afflicted with it. Although it metastasizes early and widely, it is exquisitely radiosensitive, and transient responses to this form of therapy are often dramatic. We have recently developed several monoclonal antibodies (MAb) reactive with antigens associated with this tumor. Scintigraphic and dual-label evaluations of their localization in nude mice bearing small cell carcinoma xenografts (derived from the human small cell carcinoma cell line NCI H69) were undertaken as a preliminary step in the eventual evaluation of their therapeutic potential. Anti-small cell MAb UM-MS1, 2, and 3, were labeled with 131I with the Iodobead method. Labeling efficiencies ranged from 68% to 88%. A control MAb, 225.28S (antimelanoma), was labeled with 125I by the same method. Although the labeled anti-small cell antibodies bound 20-40 times more to NCI H69 cells than did the antimelanoma control antibody, their total immunoreactive fraction was relatively low. Separate groups of nude mice bearing NCI H69-derived tumors were studied for imaging and localization with each 131I-labeled MAb. Successful imaging was achieved with two of the MAb; the quality of the images ranged from moderate to excellent. However, much of the localization to the tumors was due to nonspecific factors, as evidenced by the considerable tumor accretion of the control antibody.(ABSTRACT TRUNCATED AT 250 WORDS)
肺小细胞癌是一种致死率很高的疾病，几乎所有罹患该病的患者都会死亡。尽管它早期就会广泛转移，但对放疗极为敏感，这种治疗方式常常能带来显著的短暂反应。我们最近研发了几种与该肿瘤相关抗原发生反应的单克隆抗体（MAb）。作为最终评估其治疗潜力的初步步骤，我们对它们在携带小细胞癌异种移植瘤（源自人小细胞癌细胞系NCI H69）的裸鼠体内的定位进行了闪烁扫描和双标记评估。抗小细胞MAb UM-MS1、2和3采用碘珠法用131I进行标记。标记效率在68%至88%之间。一种对照MAb，225.28S（抗黑色素瘤），采用相同方法用125I进行标记。尽管标记的抗小细胞抗体与NCI H69细胞的结合量比抗黑色素瘤对照抗体高20至40倍，但其总免疫反应分数相对较低。分别用每组携带源自NCI H69肿瘤的裸鼠对每种131I标记的MAb进行成像和定位研究。两种MAb实现了成功成像；图像质量从中等到优秀不等。然而，肿瘤的大量定位是由非特异性因素导致的，对照抗体大量聚集在肿瘤上就证明了这一点。（摘要截短于250字）
